Chart-Typ:
Zeitraum:
| PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen |
| PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China | MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced that, through its long-standing partnership... ► Artikel lesen |
| PacBio Announces Major Advances for Revio and Vega to Lower Genome Cost and Expand Multiomic Capabilities | MENLO PARK, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced innovations to its Revio and Vega platforms... ► Artikel lesen |
| Pony.ai Granted Shenzhen's First Citywide Permit for Fully Driverless Commercial Robotaxi Operations | SHENZHEN, China, Oct. 31, 2025 /PRNewswire/ -- Pony.ai, a global leader in the large-scale commercialization of autonomous mobility, today announced that it has... ► Artikel lesen |
| Uber To Reportedly Invest In Pony AI And WeRide | WASHINGTON (dpa-AFX) - Tuesday, Uber Technologies, Inc. (UBER) is planning to make strategic investments in Pony AI and WeRide, two of China's leading autonomous driving companies, who have... ► Artikel lesen |
| Uber: Robotaxi-Offensive - Investments in Pony AI und WeRide? | Uber gibt bei Robotaxis weiter Gas: Der Ridehailing-Anbieter setzt mit Pony AI und WeRide wohl erneut auf fortgeschrittene Partner. Wie Insider berichten, ist eine Investition von 100 Millionen Dollar... ► Artikel lesen |
| XFRA W2J: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
| Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen |
| XFRA W2J: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCARISMA THERAPEUTICS... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERO THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.